Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Construction in Progress: 2013-2015

Historic Construction in Progress for Amphastar Pharmaceuticals (AMPH) over the last 1 years, with Jun 2015 value amounting to $29.5 million.

  • Amphastar Pharmaceuticals' Construction in Progress rose 49.01% to $29.5 million in Q2 2015 from the same period last year, while for Jun 2015 it was $29.5 million, marking a year-over-year increase of 49.01%. This contributed to the annual value of $25.1 million for FY2014, which is 59.82% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Construction in Progress stood at $29.5 million for Q2 2015, which was up 3.46% from $28.5 million recorded in Q1 2015.
  • Amphastar Pharmaceuticals' Construction in Progress' 5-year high stood at $29.5 million during Q2 2015, with a 5-year trough of $15.7 million in Q4 2013.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Construction in Progress value was $22.7 million (recorded in 2014), while the average stood at $23.1 million.
  • Data for Amphastar Pharmaceuticals' Construction in Progress shows a peak YoY spiked of 59.82% (in 2014) over the last 5 years.
  • Amphastar Pharmaceuticals' Construction in Progress (Quarterly) stood at $15.7 million in 2013, then soared by 59.82% to $25.1 million in 2014, then surged by 49.01% to $29.5 million in 2015.
  • Its last three reported values are $29.5 million in Q2 2015, $28.5 million for Q1 2015, and $25.1 million during Q4 2014.